
Fiasp 100IU/ml Penfill (3ml Each)
Marketer
Novo Nordisk India Pvt Ltd
Salt Composition
Insulin Aspart (100IU/ml)
Overview Fiasp 100IU/ml Penfill (3ml Each)
Fiasp 100 IU/mL Penfill (3 mL vials) manages blood glucose in individuals with type 1 and type 2 diabetes. This rapid-acting insulin lowers post-meal blood sugar, mitigating diabetes-related complications. Fiasp is usually prescribed alongside a long-acting insulin or other diabetic medications. Administered subcutaneously, your healthcare provider will instruct you on proper injection technique. Inject at meal onset or within 20 minutes. Regular blood glucose monitoring and result tracking, shared with your doctor, are crucial for dose optimization. Avoid use with low blood sugar (hypoglycemia). Inform your doctor of prior kidney, liver, or heart issues before commencing treatment. Pregnant or breastfeeding individuals require physician consultation for potential dose adjustments. Discontinue only under medical supervision. This medication complements a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Frequent side effects include hypoglycemia, headache, nasopharyngitis, and upper respiratory infections; proper dosing, consistent meals, and blood sugar monitoring help minimize these. Excessive alcohol intake can also induce hypoglycemia. Additional side effects may include injection site reactions such as redness, swelling, or hardened tissue (lipodystrophy). Weight gain is a potential consequence of insulin therapy.
Uses of Fiasp 100IU/ml Penfill (3ml Each)
Managing Diabetes
Major Benefits of Fiasp 100IU/ml Penfill (3ml Each):
Your healthcare provider will instruct you on the proper administration of this medication.
Common Side effects of Fiasp 100IU/ml Penfill (3ml Each):
- Hypoglycemia (low blood glucose level)
- Headache
- Nasopharyngitis (inflammation of the throat and nasal passages)
- Upper respiratory tract infection
How to use Fiasp 100IU/ml Penfill (3ml Each):
Your healthcare provider will instruct you on the proper administration of this medication.
How Fiasp 100IU/ml Penfill (3ml Each) works:
Rapid-acting Fiasp insulin (100 IU/mL, 3 mL penfill) begins its effects within 10 to 20 minutes of administration. Mimicking the body's natural insulin, it promotes glucose absorption by muscle and fat tissues while simultaneously inhibiting hepatic glucose production.
SAFETY ADVICE
AlcoholUNSAFE
Combining Fiasp 100 IU/ml Penfill (3ml) with alcohol is unsafe.
PregnancySAFE IF PRESCRIBED
The use of Fiasp 100 IU/ml Penfill (3 ml each) during pregnancy is usually deemed safe. Preclinical trials in animals revealed minimal or no harmful consequences for fetal development; nevertheless, data from human trials are scarce.
Breast feedingSAFE IF PRESCRIBED
Using Fiasp 100 IU/ml Penfill (3 ml each) while breastfeeding is considered safe. Research in humans indicates minimal drug transfer into breast milk, posing no known risk to the infant.
DrivingCAUTION
Driving may be impaired by excessively low or high blood glucose levels. Refrain from driving if you experience these conditions.
KidneyCAUTION
Patients with kidney impairment should use Fiasp 100 IU/ml Penfill (3 ml each) cautiously. Dosage modification may be necessary; physician consultation is advised. Routine blood glucose monitoring is recommended to guide dose adjustments.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when using Fiasp 100 IU/ml Penfill (3 ml). Dosage modifications may be necessary. Physician consultation is recommended. Close and consistent blood glucose monitoring is advised.
What if you forget to take Fiasp 100IU/ml Penfill (3ml Each) :
Failure to administer a scheduled dose of Fiasp 100 IU/ml Penfill (3ml) may result in elevated blood glucose (hyperglycemia). Monitor your blood sugar levels and adjust subsequent dosing as needed.
Facts to Know About Fiasp 100IU/ml Penfill (3ml Each)
| Label | Value |
|---|---|
| Chemical Type | Modified insulin |
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
| Behavior Class | Fast-acting insulin analogs |
